Aimigene Institute

Aimigene is a biotechnology company focused on the human microbiome and its role in health and disease. Based in Beijing, the company utilizes advanced sequencing technologies and artificial intelligence to analyze gut microbiota and develop precision health solutions. Their portfolio includes diagnostic kits for gut health assessment and a pipeline of live biotherapeutic products (LBPs) targeting metabolic and inflammatory conditions. Aimigene aims to bridge the gap between microbiome research and clinical application through its proprietary big data platform. By integrating clinical data with microbial profiles, the company identifies novel biomarkers and therapeutic targets. Their research efforts are primarily directed toward conditions such as inflammatory bowel disease, obesity, and type 2 diabetes.